SFI
INZY

Susquehanna Fundamental Investments’s Inozyme Pharma INZY Stock Holding History

Susquehanna Fundamental Investments’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-62,886
Closed -$174K – 1153
2024
Q4 		$174K Buy
+62,886
New +$239K ﹤0.01% 1018
2020
Q4 		– Sell
-10,955
Closed -$288K – 1545
2020
Q3 		$288K Buy
+10,955
New +$272K 0.01% 1078

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna Fundamental Investments's INZY Position: Q1 2025 in Review

Susquehanna Fundamental Investments sold out of Inozyme Pharma (INZY) in Q1 2025, closing a stake of 62,886 shares — an estimated $174K sold.

Susquehanna Fundamental Investments first reported a position in INZY in Q3 2020 and held it in 2 quarters. The position peaked at $288K in Q3 2020. 97 funds tracked by Wall St. Rank hold INZY as of Q1 2025.

  • Susquehanna Fundamental Investments reported no remaining Inozyme Pharma position as of Q1 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 62,886 Inozyme Pharma shares in Q1 2025, an estimated $174K.
  • Susquehanna Fundamental Investments first reported a position in Inozyme Pharma in Q3 2020 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Inozyme Pharma position peaked at $288K in Q3 2020.
  • 97 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2025, filed 14 May 2025.